Previous 10 | Next 10 |
Gainers: MoSys (NASDAQ: MOSY ) +100% . More news on: MoSys, Inc., Liberty TripAdvisor Holdings, Inc., Arcus Biosciences, Inc., Stocks on the move, , Read more ...
Atossa Therapeutics (NASDAQ: ATOS ) announces a new drug development program called COVID-19 HOPE, which is an acronym for AT-H201 in COVID-19 patients for Pulmonary Evaluation. More news on: Atossa Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Edison Nation (NASDAQ: EDNT ) +169% on over $10M order . More news on: Edison Nation, Inc., Soligenix, Inc., Atossa Therapeutics, Inc., Stocks on the move, , Read more ...
SEATTLE, April 16, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) , a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need, today announced a new drug development program called COVID-19 ...
OncoSec Medical (NASDAQ: ONCS ) -13% . More news on: OncoSec Medical Incorporated, Chimera Investment Corporation, Co-Diagnostics, Inc., Stocks on the move, , Read more ...
Gainers: Immunomedics (NASDAQ: IMMU ) +90% . More news on: Immunomedics, Inc., Akers Biosciences, Inc., Exantas Capital Corp., Stocks on the move, , Read more ...
4 Penny Stocks To Watch At The Start Of The Week This week is a short one but penny stocks are already off to a wild start. During premarket trading, headlines were flying and this time it wasn’t all about coronavirus. That is, at least, from a medical perspective. The pandemic has ca...
SEATTLE, April 02, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced recent progress with its Phase 2 study admi...
Crucial life-saving initiative led by Dr. Steven Quay for clinical trials on the safety and efficacy of a combination of FDA-approved drugs (nebulized H eparin-N-acetylcysteine in C O VID-19 P atients by E valuation of pulmonary function ( HOPE )) SEATTLE, March 30, 2020 (...
Atossa Genetics (NASDAQ: ATOS ): FY GAAP EPS of -$2.03 in-line. More news on: Atossa Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...